nach oben

Erschienen in:

25.03.2020 | Antidepressiva | Zertifizierte Fortbildung Psychiatrie

Beendigung einer Therapie mit Antipsychotika und Antidepressiva

Entstehung, Merkmale, Prävention und Behandlung von Absetzphänomenen

verfasst von: Lasse Brandt, Jonathan Henssler, Stefan Gutwinski

Erschienen in: InFo Neurologie + Psychiatrie | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Auszug

Das Thema Absetzphänomene bei psychiatrischen Medikamenten hat insbesondere in den letzten Jahren erneut zunehmende Beachtung in Klinik und Forschung erhalten. Absetzphänomene sind relevant für die sichere und erfolgreiche Planung, Umstellung und Beendigung einer Behandlung mit Antipsychotika und Antidepressiva. Der Entstehungsmechanismus, die klinischen Merkmale, die Prävention und die Behandlung von Absetzphänomenen sind der Fokus von diesem Artikel. …

Schwabe U, Paffrath D, Ludwig WD, Klauber J. Arzneiverordnungs-Report 2019

Hotopf M, Hardy R, Lewis G. Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. Brit J Psychiatry 1997; 170: 120-7PubMedCrossRef

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23PubMedCrossRef

Cerovecki A, Musil R, Klimke A, Seemüller F, Haen E, Schennach R et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: Theoretical background and practical recommendations. CNS Drugs 2013; 27: 545-72PubMedCrossRef

Brooks GW. Withdrawal from neuroleptic drugs. Am J Psychiatr. 1959; 115: 931-2PubMedCrossRef

Dilsaver SC, Greden JF. Antidepressant withdrawal phenomena. BPS 1984; 19: 237-56

Hollister LE, Eikenberry DT, Raffel S. Chlorpromazine in nonpsychotic patients with pulmonary tuberculosis. Am Rev Respir Dis 1960; 81: 562-6

Chouinard G, Samaha A-N, Chouinard V-A, Peretti C-S, Kanahara N, Takase M et al. Antipsychotic-induced dopamine supersensitivity psychosis: Pharmacology, criteria, and therapy. Psychother Psychosom 2017; 86: 189-219PubMedCrossRef

Van Leeuwen E, Petrovic M, van Driel ML, De Sutter AI, Vander Stichele R, Declercq T, et al. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. Cochrane Dementia and Cognitive Improvement Group, editor. Cochrane Database of Systematic Reviews 2018; 65: 114

10.

Henssler J, Heinz A, Brandt L, Bschor T. Antidepressant withdrawal and rebound Phenomena. Dtsch Arztebl Int 2019; 116: 355-61

11.

Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective Serotonin reuptake inhibitor discontinuation: A systematic review. Psychother Psychosom 2015; 84: 72-81PubMedCrossRef

12.

Heinz A, Daedelow L, Wackerhagen L, Di Chiara G. Addiction theory matters - why there is no dependence on caffeine or antidepressant medication (in press). Addiction Biology 2019; 1-10

13.

Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e. V. (DGPPN) (Hrsg.) S3-Leitlinie Schizophrenie AWMF-Register Nr. 038-009 Leitlinienreport Stand: 15.03.2019

14.

Geffen E, Brugman M, Hulten R, Bouvy ML, Egberts A, Heerdink ER. Patients' concerns about and problems experienced with discontinuation of antidepressants. Int J Pharmacy Practice 2007; 15: 291-3CrossRef

15.

Lader M. Benzodiazepine withdrawal states. In: Trimble M R (ed.), Benzodiazepines divided. New York: John Wiley; 1983

16.

Falkai P, Wittchen HU. Diagnostisches und statistisches Manual psychischer Störungen: DSM-5. 2015

17.

Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. BPS 1998; 44: 77-87PubMedCrossRef

18.

Berber MJ. FINISH: remembering the discontinuation syndrome. Flu-like symptoms, insomnia, nausea, imbalance, sensory disturbances, and hyperarousal (anxiety/agitation). J Clin Psychiatry 1998; 59: 255PubMedCrossRef

19.

Benmansour S, Altamirano AV, Jones DJ, Sanchez TA, Gould GG, Pardon M-C et al. Regulation of the norepinephrine transporter by chronic administration of antidepressants. Biological Psychiatry 2004; 55: 313-6PubMedCrossRef

20.

Kittler K, Lau T, Schloss P. Antagonists and substrates differentially regulate serotonin transporter cell surface expression in serotonergic neurons. Eur J Pharmacology 2010; 629: 63-7PubMedCrossRef

21.

Mirza NR, Nielsen EØ, Troelsen KB. Serotonin transporter density and anxiolytic-like effects of antidepressants in mice. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 858-66PubMedCrossRef

22.

Benmansour S, Owens WA, Cecchi M, Morilak DA, Frazer A. Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. J Neurosci; 22: 6766-72PubMedPubMedCentralCrossRef

23.

Klomp A, Hamelink R, Feenstra M, Denys D, Reneman L. Increased response to a 5-HT challenge after discontinuation of chronic serotonin uptake inhibition in the adult and adolescent rat brain. PLoS ONE 2014; 9: e99873-10PubMedPubMedCentralCrossRef

24.

Reidenberg MM. Drug discontinuation effects are part of the pharmacology of a drug. J Pharmacol Exp Ther 2011; 339: 324-8PubMedCrossRef

25.

Dilling H, Freyberger HJ. Taschenführer zur ICD-10-Klassifikation psychischer Störungen. Göttingen, Germany: Hogrefe 2013

26.

Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 2007; 27: 2979-86PubMedCrossRef

27.

Samaha AN, Reckless GE, Seeman P, Diwan M, Nobrega JN, Kapur S. Less is more: Antipsychotic drug effects are greater with transient rather than continuous delivery. Biol Psychiatry 2008; 64: 145-52PubMedCrossRef

28.

Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology 2000; 152: 174-80PubMedCrossRef

29.

Leucht S, Davis JM. Do antipsychotic drugs lose their efficacy for relapse prevention over time? Br J Psychiatry 2017; 211: 127-9PubMedCrossRef

30.

Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012; 379: 2063-71CrossRef

31.

Takeuchi H, Kantor N, Sanches M, Fervaha G, Agid O, Remington G. One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo: meta-analysis. Br J Psychiatry 2017; 211: 137-43PubMedCrossRef

32.

Taylor MJ, Yim S. Is there rebound psychosis on withdrawal of antipsychotic medication in schizophrenia? Schizophrenia Res 2018; 1-2

33.

El-Mallakh RS, Briscoe B. Studies of long-term use of antidepressants: how should the data from them be interpreted? CNS Drugs 2012; 26: 97-109PubMedCrossRef

34.

Lacoursiere RB, Spohn HE, Thompson K. Medical effects of abrupt neuroleptic withdrawal. Comprehensive Psychiatry 1976; 17: 285-94PubMedCrossRef

35.

Tranter R, Healy D. Neuroleptic discontinuation syndromes. J Psychopharmacol 1998; 12: 401-6PubMedCrossRef

36.

Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: A systematic review. Psychother Psychosom 2015; 84: 72-81PubMedCrossRef

37.

Chouinard G, Chouinard V-A. New classification of selective serotonin reuptake inhibitor withdrawal. Psychother Psychosom 2015; 84: 63-71PubMedCrossRef

38.

Perahia DG, Kajdasz DK, Desaiah D, Haddad PM. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. J Affect Disord 2005; 89: 207-12PubMedCrossRef

39.

Baldwin DS, Montgomery SA, Nil R, Lader M. Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol 2005; 10: 73-12PubMedCrossRef

40.

Markowitz JS, DeVane CL, Liston HL, Montgomery SA. An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram. Int Clin Psychopharmacol 2000; 15: 329-33PubMedCrossRef

41.

Greenberg LM, Roth S. Differential effects of abrupt versus gradual withdrawal of chlorpromazine in hospitalized chronic schizophrenic patients. Am J Psychiatry 1966; 123: 221-6PubMedCrossRef

42.

Emsley R, Nuamah I, Gopal S, Hough D, Fleischhacker WW. Relapse after antipsychotic discontinuation in schizophrenia as a withdrawal phenomenon vs illness recurrence: A post hoc analysis of a randomized placebo-controlled study. J Clin Psychiatry 2018; 79

43.

DGPPN, BÄK, KBV, AWMF. S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression - Langfassung, 2. Auflage. Version 5; 2017

44.

Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry 2019; 6: 538-46PubMedCrossRef

45.

Keuthen NJ, Cyr P, Ricciardi JA, Minichiello WE, Buttolph ML, Jenike MA. Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine. J Clin Psychopharmacol 1994; 14: 206-7PubMedCrossRef

46.

Benazzi F. Fluoxetine for the treatment of SSRI discontinuation syndrome. Int J Neuropsychopharmacol 2008; 11: 27-2

47.

Giakas WJ, Davis JM. Intractable withdrawal from venlafaxine treated with fluoxetine. Psychiatric Annals 1997; 27: 85-92CrossRef

Titel: Beendigung einer Therapie mit Antipsychotika und Antidepressiva
Entstehung, Merkmale, Prävention und Behandlung von Absetzphänomenen
verfasst von: Lasse Brandt
Jonathan Henssler
Stefan Gutwinski
Publikationsdatum: 25.03.2020
Verlag: Springer Medizin
Schlagwörter: Antidepressiva
Antipsychotika
Antidepressiva
Fluoxetin
Antipsychotika
Erschienen in: InFo Neurologie + Psychiatrie / Ausgabe 3/2020
Print ISSN: 1437-062X
Elektronische ISSN: 2195-5166
DOI: https://doi.org/10.1007/s15005-020-1293-6

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Digitale Interventionen etablieren sich bei Angsterkrankungen

Welche Effekte hat das Absetzen von Cannabis bei MS-Patienten?

Blended Treatment: Theoretisch gut, in der Umsetzung mühsam

Verlängerte Dosierungsintervalle von Natalizumab reduzieren das PML-Risiko

Deutsche S3-Leitlinie Schizophrenie: Die rTMS ist jetzt "offiziell"

Parkinson durch Betablocker?